INBX (Inhibrx Biosciences) Beginning Cash Position: $124.22 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBX Inhibrx Biosciences Inc INBX
6 GF Score
Price $98.67
! 5 Warning Signs
View Full Analysis

What is Inhibrx Biosciences Beginning Cash Position?

Inhibrx Biosciences INBX +6.47% 6 Beginning Cash Position is $124.22 Mil as of Mar. 2026. GuruFocus rates INBX with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

Inhibrx Biosciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $124.22 Mil.

Inhibrx Biosciences's quarterly Beginning Cash Position declined from Sep. 2025 ($186.57 Mil) to Dec. 2025 ($153.09 Mil) and declined from Dec. 2025 ($153.09 Mil) to Mar. 2026 ($124.22 Mil).

Inhibrx Biosciences's annual Beginning Cash Position increased from Dec. 2023 ($273.87 Mil) to Dec. 2024 ($277.92 Mil) but then declined from Dec. 2024 ($277.92 Mil) to Dec. 2025 ($152.60 Mil).

Inhibrx Biosciences Beginning Cash Position Related Terms

Inhibrx Biosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Inhibrx Biosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibrx Biosciences Beginning Cash Position Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
0.00 273.87 277.92 152.60

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.60 216.52 186.57 153.09 124.22
INBX
6GF Score
Inhibrx Biosciences Inc INBX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibrx Biosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $124.22 Mil mean?
Inhibrx Biosciences (INBX) has a Beginning Cash Position of $124.22 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Inhibrx Biosciences and its competitors.
Is Inhibrx Biosciences' Beginning Cash Position too high?
Inhibrx Biosciences' current Beginning Cash Position is $124.22 Mil. Overall, Inhibrx Biosciences has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' Beginning Cash Position compare to JBIO and NVAX?
Inhibrx Biosciences' Beginning Cash Position of $124.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Inhibrx Biosciences and its competitors. Inhibrx Biosciences's current Beginning Cash Position is $124.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current Beginning Cash Position of $124.22 Mil. The current Beginning Cash Position is $124.22 Mil. Inhibrx Biosciences' overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current Beginning Cash Position is $124.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibrx Biosciences Business Description

Address 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
6GF Score

Get the complete analysis for INBX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$98.67
Price